Breaking News

Tweet TWEET

Morning Research on Teva Pharma, Orexigen Therapeutics, Zoetis, and Novartis

 Morning Research on Teva Pharma, Orexigen Therapeutics, Zoetis, and Novartis

PR Newswire

LONDON, April 3, 2013

LONDON, April 3, 2013 /PRNewswire/ --

Major pharmaceutical companies such as Zoetis Inc. (NYSE: ZTS) and Novartis AG
(NYSE: NVS) have been facing increasing competition from generic drugs.
Recently, Novartis lost a major patent case in India for its cancer drug. With
patents on several blockbuster drugs scheduled to expire in 2013, competition
from generic drugs is expected to increase. The key for major drug
manufacturers will be to boost their product pipeline. Another major trend in
the healthcare sector has been the Affordable Care Act (ACA), which was upheld
by the Supreme Court last year. The ACA is expected to have a significant
impact on major drug manufacturers as well as on biotechnology companies such
as Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), and Orexigen Therapeutics
Inc. (NASDAQ: OREX). On Tuesday, shares of all companies except Novartis AG
ended lower even as the broad market posted gains. StockCall has posted free
technical research reports on NVS, OREX, ZTS, and NVS and these can be
accessed by signing up at

http://www.stockcall.com/analysis

Novartis AG shares touched a 52-week high of $71.75 in trading on Tuesday. The
stock ended the day 0.37% higher at $71.32, taking its gains in the last three
trading sessions to over 1.20%. Shares of NVS have had an excellent run this
year, gaining nearly 17%, compared to a gain of a little over 10% for the S&P
500. The stock has seen a series of highs over the past few months, which is a
bullish signal. Download the free report on NVS upon registration at

http://www.StockCall.com/NVS040313.pdf

Shares of Zoetis Inc. ended marginally lower in Tuesday's trading session. The
stock finished the day 0.12% lower at $32.55. Earlier in the day, Zoetis'
shares had risen to a high of $33.13. However, the stock failed to hold on to
its momentum. The company's shares have gained nearly 5% since the stock began
trading in February this year. The stock has an all-time high of $35.42. Its
MACD chart is currently giving bearish signals. ZTS technical report can be
accessed for free by signing up at

http://www.StockCall.com/ZTS040313.pdf

Shares of Orexigen Therapeutics Inc. fell sharply in trading yesterday. The
stock fell to an intra-day low of $6.04 before finishing the day 1.14% lower
at $6.09. Despite the pullback on Tuesday, Orexigen's shares have gained 3.75%
in the last three sessions. The company's shares are currently facing stiff
resistance at around $6.60. The stock is currently trading well above its
50-day and 200-day moving averages, which is a bullish signal. Shares of OREX
have outperformed the broad market so far in 2013, gaining 16%. The free
report on OREX can be downloaded by signing up now at

http://www.StockCall.com/OREX040313.pdf

Shares of Teva Pharmaceutical Industries Ltd. fell in trading on Tuesday;
however, the losses were limited. The stock ended the day 0.05% lower at
$39.55 after touching an intra-day low of $39.43. Teva's shares have had a
decent run in 2013 so far. Year-to-date, the stock has gained nearly 6.80%.
The stock had rallied at the beginning of March, however, it saw a sharp
pullback after failing to break through $41 resistance level. The stock's MACD
is currently trading below the signal line, which is a bearish signal. Free
report on TEVA can be accessed by registering at

http://www.StockCall.com/TEVA040313.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at

http://www.stockcall.com

SOURCE StockCall.com

Contact: Contact Person:William T. Knight, Email: info@stockcall.com, Contact
Number: +1(646)396-9857 (9:00 am EST - 01:30 pm EST)